Delivery of cefotaxime to the brain via intranasal administration

References

• Gary PY. (1987). Cephalosporins for bacterial meningitis. West J Med, 146:607–608.
   PubMedGoogle Scholar
• Pedro FV, Carmen C, Roman P, Tubau FE, Javier ML, Josefina L et al. (1996). High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother, 40:218–220.
   PubMed Web of Science ®Google Scholar
• Nelson JD. (1985). Emerging role of cephalosporins in bacterial meningitis. Am J Med, 79:47–51.
   PubMed Web of Science ®Google Scholar
• Puddicombe JB, Wali SS, Greenwood BM. (1984). A field trial of a single intramuscular injection of long-acting chloramphenicol in the treatment of meningococcal meningitis. Trans R Soc Trop Med Hyg, 78:399–403.
   PubMed Web of Science ®Google Scholar
• Nau R, Prange HW, Muth P, Mahr G, Menck S, Kolenda H et al. (1993). Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother, 37:1518–1524.
   PubMed Web of Science ®Google Scholar
• Tsai TH, Chen YF, Chen KC, Shum AY, Chen CF. (2000). Concurrent quantification and pharmacokinetic analysis of cefotaxime in rat blood and brain by microdialysis and microbore liquid chromatography. J Chromatogr B Biomed Sci Appl, 738:75–81.
   PubMed Web of Science ®Google Scholar
• Sjölin J. (1991). High-dose corticosteroid therapy in human septic shock: has the jury reached a correct verdict? Circ Shock, 35:139–151.
   PubMedGoogle Scholar
• Maurice JA, Enno DW, Dick T, Ron AM. (2010). Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother, 54:1734–1741.
   PubMed Web of Science ®Google Scholar
• Turnidge JD. (1995). Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Diagn Microbiol Infect Dis, 22:57–69.
   PubMed Web of Science ®Google Scholar
• Shilpey MT. (1985). Transport of molecules from nose to brain: transneuronal anteograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin–horseradish peroxidase applied to the nasal mucosa. Brain Res Bull, 15:129–142.
   PubMedGoogle Scholar
• Baker H, Spencer RF. (1986). Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res, 63:461–473.
   PubMed Web of Science ®Google Scholar
• Illum L. (2003). Nasal drug delivery–possibilities, problems and solutions. J Control Release, 87:187–198.
   PubMed Web of Science ®Google Scholar
• Mathison S, Nagilla R, Kompella UB. (1998). Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target, 5:415–441.
   PubMed Web of Science ®Google Scholar
• Frey WH, Liu L, Chen XQ, Thorne RG, Fawerrtt JR, Ala TA et al. (1997). Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv, 4:87–92.
   Web of Science ®Google Scholar
• Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey II WH. (1998). Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis, 1:35–44.
   PubMedGoogle Scholar
• Vaka SR, Sammeta SM, Day LB, Murthy SN. (2009). Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci, 98:3640–3646.
   PubMed Web of Science ®Google Scholar
• Kandimalla KK, Donovan MD. (2005). Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci, 94:613–624.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH 2nd. (2007). Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol, 2:81–86.
   PubMed Web of Science ®Google Scholar
• Smith J, Wood E, Dornish M. (2004). Effect of chitosan on epithelial cell tight junctions. Pharm Res, 21:43–49.
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. (1999). Effect of chitosan on epithelial permeability and structure. Int J Pharm, 182:21–32.
   PubMed Web of Science ®Google Scholar
• Schmidt MC, Simmen D, Hilbe M, Boderke P, Ditzinger G, Sandow J et al. (2000). Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J Pharm Sci, 89:396–407.
   PubMed Web of Science ®Google Scholar
• Richard LY, Hartmut D. (1985). Rapid chromatographic conditions of cefotaxime and its metabolite in biological fluids. J Chromatogr B Biomed Sci Appl, 341:131–138.
   Google Scholar
• Brisson AM, Fourtillan JB. (1981). Determination of cephalosporins in biological material by reversed-phase liquid column chromatography. J Chromatogr, 223:393–399.
   PubMed Web of Science ®Google Scholar
• Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M. (1980). Nasal absorption of propranolol in humans. J Pharm Sci, 69:1240.
   PubMed Web of Science ®Google Scholar
• Chamberlain J, Coombes JD, Dell D, Fromson JM, Ings RJ, Macdonald CM et al. (1980). Metabolism of cefotaxime in animals and man. J Antimicrob Chemother, 6 (Suppl A):69–78.
   PubMed Web of Science ®Google Scholar
• Coombes JD. (1982). Metabolism of cefotaxime in animals and humans. Rev Infect Dis, 4 (Suppl):S325–S332.
   PubMedGoogle Scholar
• Limbert M, Seibert G, Schrinner E. (1982). The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability. Infection, 10:97–100.
   PubMed Web of Science ®Google Scholar